MOE > サポート > 論文一覧

概要

論文一覧

MOEを使用した論文の一覧です。研究の参考にご利用下さい。
(現在弊社で把握しているものであり、MOEを使用した論文の全てを掲載しているわけではありません。
論文を出版された方、一覧に掲載されていない論文をご存知の方は、こちらまでお知らせいただけましたら幸いです。)

また、CCG社のMOE Citationsページもご参照ください。

References citing MOE

  1. Amari, S.; Aizawa, M.; Zhang, J.; Fukuzawa, K.; Mochizuki, Y.; Iwasawa, Y.; Nakata, K.; Chuman, H.; Nakano, T. VISCANA: Visualized Cluster Analysis of Protein-Ligand Interaction Based on the ab Initio Fragment Molecular Orbital Method for Virtual Ligand Screening,J. Chem. Inf. Model., 2006, 46, 221-230.
  2. Arakawa, M.; Hasegawa, K.; Funatsu, K. Tailored scoring function of Trypsin-benzamidine complex using COMBINE descriptors and support vector regression,Chemom. Intell. Lab. Syst., 2008, 92, 145-151.
  3. Auzanneau, F.-I.; Sourial, E.; Schmidt, J.M.; Feher, M. Stochastic conformational search on the Lewis X (Lex) trisaccharide and three Lex analogues,Can. J. Chem., 2002, 80, 1088-1095.
  4. Azuma, M.; Kabe, Y.; Kuramori, C.; Kondo, M.; Yamaguchi, Y.;, Handa, H. Adenine Nucleotide Translocator Transports Haem Precursors into Mitochondria,PLoS ONE, 2008, 3, e3070.
  5. Bai, J.-Y.; Ding, W.-G.; Kojima, A.; Seto, T.; Matsuura, H.. Putative binding sites for arachidonic acid on the human cardiac Kv1. 5 channelBritish journal of pharmacology, Wiley Online Library, 2015, Vol. 172(22), pp. 5281-5292
  6. Bajorath, J.. Selected concepts and investigations in compound classification, molecular descriptor analysis, and virtual screening.J. Chem. Inf. Comput. Sci., 2001, 41, 233-245.
  7. Baraldi, P.G.; Cacciari, B.; Moro, S.; Spalluto, G.; Pastorin, G.; Da Ros, T.; Klotz, K.-N.; Varani, K.; Gessi, S.; Borea, P. A.. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists,J. Med. Chem., 2002, 45, 770-780.
  8. Baraldi, P.G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Moro, S.; Klotz, K.-N.; Leung, E.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P.A.. Pyrazolo [4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selection human A(3) adenosine receptor antagonists: Influence of the chain at the N(8) pyrazole nitrogen,J. Med. Chem., 2000, 43, 4768-4780.
  9. Baudry, J.; Li, W.; Pan, L.; Berenbaum, M.R.; Schuler, M.A.. Molecular docking of substrates and inhibitors in the catalytic site of CYP6B1, an insect cytochrome P450 monooxygenase, Protein Eng., 2003, 16, 577-587.
  10. Baurin, N.; Mozziconacci JC.; Arnoult, E.; Chavatte, P; Marot, C.; Morin-Allory, L.. 2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database, J. Chem. Inf. Comput. Sci., 2004, 44, 276-285.
  11. Cen, X.; Nitta, A.: Ohya, S.; Zhao, Y.; Ozawa, N.;, Mouri, A.; Ibi, D.; Wang, L.; Suzuki, M.; Saito, K.; Ito, Y.; Kawagoe, T.; Noda, Y.; Ito, Y.; Furukawa, S.; Nabeshima, T.. An Analog of a Dipeptide-Like Structure of FK506 Increases Glial Cell Line-Derived Neurotrophic Factor Expression through cAMP Response Element-Binding Protein Activated by Heat Shock Protein 90/Akt Signaling Pathway,J. Neurosci., 2006, 26, 3335-3344.
  12. Chen. R.; Yokoyama, M.; Sato, H.; Reilly, C.; Mansky, L.M.. Human Immunodeficiency Virus Mutagenesis during Antiviral Therapy: Impact of Drug-Resistant Reverse Transcriptase and Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors on Human Immunodefiency Virus Type 1 Mutation Frequencies, J. Virol., 2005, 79, 12045-12057.
  13. Chou. K.-C.; Howe, W.J. Prediction of the tertiary structure of the beta-secretase zymogen. Biochemical and Biophysical Research Communications, 2002, 292, 702-708.
  14. Daines, R.A.; Pendrak, I.; Sham, K.; Van Aller, G.S.; Konstantinidis, A.K.; Lonsdale, J.T.; Janson, C.A.; Qiu, X.; Brandt, M.; Khandekar, S.S.; Silverman, C.; Head, M.S.. First x-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J. Med. Chem., 2003, 46, 5-8.
  15. Demura, M.; Yoshida, T.; Hirokawa, T.; Kumaki, Y.; Aizawa, T.; Nitta, K.; Bitter, I.; Toth ,K.. Interaction of dopamine and acetylcholine with an amphiphilic resorcinarene receptor in aqueous micelle system, Bioorg. Med. Chem. Lett., 2005, 15, 1367-1370.
  16. Duffy, K.J.; Shaw, A.N.; Delorme, E.; Dillon, S.B.; Erickson-Miller, C.; Giampa, L.; Huang, Y.; Keenan, R.M.; Lamb, P.; Liu, N.; Miller, S.G.; Price, A.T.; Rosen, J.; Smith, H.; Wiggall, K.J.; Zhang, L.; Luengo, J.I.. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 1. Discovery and optimization of salicylaldehyde thiosemicarbazone thrombopoietin mimics, J. Med. Chem., 2002, 45, 3573-3575.
  17. Duffy, K.J.; Price, A.T.; Delorme, E.; Dillon, S.B.; Duquenne, C.; Erickson-Miller, C.; Giampa, L.; Huang, Y.; Keenan, R.M.; Lamb, P.; Liu, N.; Miller, S.G.; Rosen, J.; Shaw, A.N.; Smith, H.; Wiggall, K.J.; Zhang, L.; Luengo, J.I.. Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d] imidazole thrombopoietin mimics, J. Med. Chem., 2002, 45, 3576-3578.
  18. Ermondi, G.; Caron, G.; Lawrence, R.; Longo, D.. Docking studies on NSAID/COX-2 isozyme complexes using Contact Statistics analysis.J. Comput. Aided. Mol. Des., 2004, 18, 683-696.
  19. Esposito, E.X.; Baran, K.; Kelly, K.; Madura, J.D.. Docking of sulfonamides to carbonic anhydrase II and IV.J. Molec. Graph. and Mod., 2000, 18, 283-289.
  20. Esposito, E.X.; Baran, K.; Kelly, K.; Madura, J.D.. Docking substrates to metalloenzymes.Molecular Simulation, 2000, 24, 293-306.
  21. Feher, M.; Schmidt, J.M.. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry, J. Chem. Inf. Comput. Sci., 2003, 43, 218-227.
  22. Feher, M.; Schmidt, J. Metric and multidimensional scaling: Efficient tools for clustering molecular conformations,J. Chem. Inf. Comput. Sci., 2001, 41, 346-353.
  23. Feher, M.; Schmidt, J.M.. Multiple flexible alignment with SEAL: A study of molecules acting on the colchicine binding site,J. Chem. Inf. Comput Sci. , 2000, 40, 495-502.
  24. Feher, M.; Sourial, E.; Schmidt, J.M.. A simple model for the prediction of blood-brain partitioning. Int. J. Pharmaceutics, 2000, 201, 239-247.
  25. Fukiage, C.; Nakajima, E.; Ma, H.; Azuma, M.; Shearer, T.R.. Charaterization and regulation of lens-specific calpain Lp82, J. Biol. Chem., 2002, 277, 20678-20685.
  26. Fukuhara, T.; Kobayashi, K.; Kanayama, Y.; Enomoto, S.; Kondo, T.; Tsunekawa, N.; Nemoto, M.; Ogasawara, N.; Inagaki, K.; Tamura, T.. Identification and characterization of the zosA gene involved in copper uptake in Bacillus subtilis 168, Bioscience, Biotechnology, and Biochemistry, 2016, 80, 600-609.
  27. Gagnon, L.; DiMarco, M.; Kirby, R.; Zacharie, B.; Penney, C.L.. D-LysAsnProTyr tetrapeptide: a novel B-cell stimulant and stabilized bursin mimetic, Vaccine, 2000, 18, 1886-1892.
  28. Gao, H. Application of BCUT metrics and genetic algorithm in binary QSAR analysis,J. Chem. Inf. Comput. Sci., 2001, 41, 402-407.
  29. Gao, H.; Williams, C.; Labute, P; Bajorath, J.
    Binary quantitative structure – activity relationship (QSAR) analysis of estrogen receptor ligands.J. Chem. Inf. Comput. Sci., 1999, 39, 164-168.
  30. 「基礎と実習 バイオインフォマティクス」郷通子、高橋健一 編、2004, 共立出版(株)
  31. Godden, J.W.; Furr, J.R.; Bajorath, J.Recursive median partitioning for virtual screening of large databases, J. Chem. Inf. Comput. Sci., 2003, 43, 182-188.
  32. Godden, J.W.; Bajorath, J.. Chemical Descriptors with Distinct Levels of Information Content and Varying Sensitivity to Differences between Selected Compound Databases Identified by SE-DSE Analysis,J. Chem. Inf. Comput. Sci., 2002, 42, 87-93.
  33. Godden, J.W.; Xue, L.; Kitchen, D.B.; Stahura, F.L.; Schermerhorn, E.J.; Bajorath, J. Median partitioning.. A novel method for the selection of representative subsets from large compound pools, J. Chem. Inf. Comput. Sci. , 2002, 42, 885-893.
  34. Godden, J.W.; Stahura, F.L.; Bajorath, J.. Variability of molecular descriptors in compound databases revealed by shannon entropy calculations, J. Chem. Inf. Comput. Sci., 2000, 40, 796-800.
  35. Godden, J.W.; Xue, L.; Bajorath, J.. Combinatorial preferences affect molecular similarity/diversity calculations using binary fingerprint and Tanimoto coefficients,J. Chem. Inf. Comput. Sci., 2000, 40, 163-166.
  36. Goto, J.; Kataoka, R.; Hirayama, N.. Ph4Dock: Pharmacophore-Based Protein-Ligand Docking. J. Med. Chem., 2004, 47, 6804-6811.
  37. Goto, J.; Kataoka, R.; Muta H.; Hirayama, N.. ASEDock-Docking Based on Alpha Spheres and Excluded Volumes. J. Chem. Inf. Model., 2008, 48, 583-590.
  38. Giuliano, B.; Clayton, S.; Nigel, J., W.; Franco, L.. In Silico Prediction of Volume of Distribution in Human Using Linear and Nonlinear Models on a 669 Compound Data Set. J. Med. Chem., 2009, 52, 4488-4495.
  39. Hashimoto, M.; Taguchi, T.; Ishikawa, K.; Mori, R.; Hotta, A.; Watari, S.; Katakawa, K.; Kumamoto, T.; Okamoto, S.; Ichinose, K.. Unveiling Two Consecutive Hydroxylations: Mechanisms of Aromatic Hydroxylations Catalyzed by Flavin-Dependent Monooxygenases for the Biosynthesis of Actinorhodin and Related Antibiotics, ChemBioChem 2019, 20, 1-6.
  40. Hamada T, Kawashima M, Watanabe H, Tagami J, Senpuku H.. Molecular interactions of surface protein peptides of Streptococcus gordonii with human salivary components.Infect. Immun. 2004, 72(8), 4819-26.
  41. Hasegawa, K.; Koyama, M.; Funatsu, K.. Quantitative Prediction of Regioselectivity Toward Cytochrome P450/3A4 Using Machine Learning Approaches.
    Mol. Inf. 2010, 29, 243-249.
  42. Hasegawa, K.; Funatsu, K.. Advanced PLS Technique Focusing on Visualization and Chemical Interpretation – SOMPLS Analysis of Serine Protease Inhibitors -.
    J. Comput. Aided. Chem., 2010, 11, 56-61.
  43. Hidaka, K.; Kimura, T.; Abdel-Rahman, H., M.; Nguyen, J.-T.; McDaniel, K., F.; Kohlbrenner, W., E.; Katsuki, N.; Tanaka, Y.; Matsumoto, H.; Wang, J.; Hayashi, Y.; Kempf, D., J.; Kiso, Y.. Small-Sized Human Immunodeficiency Virus Type-1 Protease Inhibitors Containing Allophenylnorstatine to Explore the S2‘ Pocket. J. Med. Chem., 2009, 52, 7604-7617.
  44. Howarth, N.M.; Purohit, A.; Robinson, J.J.; Vicker, N.; Reed, M.J.; Potter, B.V.L.. Estrone 3-sulfate mimics, inhibitors of estrone sulfatase activity: Homology model construction and docking studies, Biochemistry, 2002, 41, 14801-14814.
  45. Huang, J.; Hamasaki, T.; Ozoe, F.; Ohta, H.; Enomoto, K.; Kataoka, H.; Sawa Y.; Hirota, A.; Ozoe, Y.. Identification of Critical Structural Determinants Responsible for Octopamine Binding to the R-Adrenergic-like Bombyx mori Octopamine Receptor. Biochemistry, 2007, 46, 5896-5903.
  46. Ishii, K.; Kondo, K.; Takahashi, M.; Kimura M.; Endoh, M.. An amino acid residue whose change by mutation affects drug binding to the HERG channel,FEBS Letters, 2001, 506, 191-195.
  47. Ito, S.; Nakahari, T.; Yamamoto, D.. The structural feature surrounding glycated lysine residues in human hemoglobin,Biomed. Res.,2011,32.217-223.
  48. Ito, S.; Nakahari, T.; Yamamoto, D.. Relationship between impaired glycation and the N-terminal structure of the Hb G¥örwihl [$5 (A2) Pro->Ala] variant,Hemoglobin,2010,34.151-156.
  49. Ito, S.; Yamamoto, D.. Identification of two bromocresol purple binding sites on human serum albumin, Clin. Chim. Acta, 2010,411.1536-1538.
  50. 片岡良一、後藤純一「バイオインフォマティクスと創薬」ポストシークエンスタンパク質実験法 1ー全タンパク質の解析ー 大島泰郎、鈴木紘一、藤井義明、村松喬 編、p191-201、 2002,(株)東京化学同人
  51. 片岡良一、後藤純一ASEDock—結合部位の形状に基づくドッキングMolecular Science, 2008, 2, NP008.
  52. Kataoka, R.; Amari, S.; Ikegami, T.; Hirayama, N. HLABAP: HLA Class I-Binding Antigenic Peptide Predictor, CBIJ., 2020, 20, 1-4.
  53. Katada, S.; Hirokawa, T.; Oka, Y.; Suwa, M.; Touhara, K.. Structural Basis for a Broad But Selective Ligand Spectrum of a Mouse Olfactory Receptor: Mapping the Odorant-Binding Site, J. Neurosci., 2005, 25, 1806-1815.
  54. Kinomoto, M.; Yokoyama, M.; Sato, H.; Kojima, A.; Kurata, T.; Ikuta, K.; Sata, T.; Tokunaga, K.. Amino Acid 36 in the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Controls Fusogenic Activity: Implications for the Molecular Mechanism of Viral Escape from a Fusion Inhibitor,J. Virol., 2005, 79, 5996-6004.
  55. Kinomoto, M.; Appiah-Opong, R.; Brandful, J.A.M.; Yokoyama, M.; Nii-Trebi, N.; Ugly-Kwame, E.; Sato, H.; Ofori-Adjei, D.; Kurata, T.; Barre-Sinoussi, F.O.; Sata, T.; Tokunaga, K.. HIV-1 proteases from drug-na ve West African patients are differentially less susceptible to protease inhibitors,
    Clin. Infect. Dis., 2005, 41, 243-251.
  56. Kiso, A.; Hidaka, K.; Kimura, T.; Hayashi, Y.; Nezami, A.; Freire, E.; Kiso, Y.. Search for substrate-based inhibitors fitting the S2′ space of malarial aspartic protease plaasmepsin II, J. Peptide Sci., 2004, 10, 641-647.
  57. Kobayashi, K.; Oishi, S.; Hayashi, R.; Tomita, K.; Kubo, T.; Tanahara, N.; Ohno, H.; Yoshikawa, Y.; Furuya, T.; Hoshino, M.; Fujii, N.. Structure-Activity Relationship Study of a CXC Chemokine Receptor Type 4 Antagonist, FC131, Using a Series of Alkene Dipeptide Isosteres, Journal of Medicinal Chemistry,2012,55.2746-2757.
  58. Kojima, A.; Fukushima, Y.; Ito, Y.; Ding, WG.; Ueda, R.; Seto, T.; Kitagawa, H.; Matsuura, H.. Interactions of propofol with human voltage-gated Kv1.5 channel determined by docking simulation and mutagenesis analyses, J Cardiovasc Pharmacol, 2018, 71, 10-18.
  59. Kotake, T.; Hayashi, Y.; Rajesh, S.; Mukai, Y.; Takiguchi, Y.; Kimura, T.; Kiso, Y.. Design and synthesis of a new polymer-supported Evans-type oxazolidinone: an efficient chiral auxiliary in the solid-phase asymmetric alkylation reaction,Tetrahedron, 2005, 61, 3819-3833.
  60. Kubo, Y.; Yokoyama, M.; Yoshii, H.; Mitani, C.; Tominaga, C.; Tanaka, Y.; Sato, H.; Yamamoto, N.. Inhibitory role of CXCR4 glycan in CD4-independent X4-tropic human immunodeficiency virus type 1 infection and its abrogation in CD4-dependent infection, J. Gen. Virol., 2007, 88, 3139-3144.
  61. Kurotsuchi A.; Murakumo Y.; Jijiwa M.; Kurokawa K.; Itoh Y.; Kodama Y.; Kato T.; Enomoto A.; Asai N.; Terasaki H.; Takahashi M.. Analysis of DOK-6 function in downstream signaling of RET in human neuroblastoma cells, Cancer Sci., 2010, 101, 1147-1155.
  62. Labute, P.; Nilar, S.; Williams, C.. A Probabilistic Approach to High Throughput Drug Discovery,Combinatorial Chemistry & High Throughput Screening, 2002, 5, 135-145.
  63. Labute, P.; Williams, C.; Feher, M.; Sourial, E.; Schmidt, J.M.. Flexible alignment of small molecules,J. Med. Chem., 2001, 44, 1483-1490.
  64. Labute, P.. A widely applicable set of descriptors, J. Mol. Graphics Mod. , 2000, 18, 464-477.
  65. Li, X.; Baudry, J; Berenbaum, M.R.; Schuler, M.A.. Structural and functional evolution of insect CYP6B proteins: from specialist to generalist P450,Proc. Natl. Acad. Sci. , 2004, 101, 2939-2944.
  66. Lindstrom, A.; Pettersson, F; Almqvist, F; Berglund, A.; Kihlberg, J.; Linusson, A.. Hierarchical PLS Modeling for Predicting the Binding of a Comprehensive Set of Structurally Diverse Protein-Ligand Complexes, J. Chem. Inf. Model. , 2006, 46, 1154-1167.
  67. Manavalan, B.; Murugapiran, S.K.; Lee, G.; Choi, S.. Molecular modeling of the reductase domain to elucidate the reaction mechanism of reduction of peptidyl thioester into its corresponding alcohol in non-ribosomal peptide synthetases. BMC Struct. Biol., 2010, 10:1.
  68. Meagher, K. L.; Lerner, M. G.; Carlson, H. A.. Refining the Multiple Protein Structure Pharmacophore Method: Consistency across Three Independent HIV-1 Protease Models, J. Med. Chem., 2006, 49, 3478-3484.
  69. Misumi, S.; Endo, M.; Mukai, R.; Tachibana K.;Umeda M.; Honda, T.,Takamune, N.; Shoji, S.. A Novel Cyclic Peptide Immunization Strategy for Preventing HIV-1/AIDS Infection and Progression, J. Biol. Chem. , 2003, 278, 32335-32343.
  70. Motomura, K.; Oka, T.; Yokoyama, M.; Nakamura, H.;Mori, H.; Ode, H.; Hansman, GS.; Katayama, K.; Kanda, T.; Tanaka, T.; Takeda, N.; Sato, H.. the Norovirus Surveillance Group of Japan: Identification of Monomorphic and Divergent Haplotypes in 2006/2007 Norovirus GII/4 Epidemic Population by Genome-wide Tracing of Evolutionary History, J. Virol., 2008, 82, 11247-11262.
  71. Murayama, N.; Imai, N.; Nakane, T.; Shimizu, M.;Yamazaki, H.. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes, Biochem. Pharmacol. , 2007, 73, 2020-2026.
  72. Nagata, N.; Iwata, N.; Hasegawa, H.; Fukushi, S.; Yokoyama, M.; Harashima, A.; Sato, Y.; Saijo, M.; Morikawa, S.; Sata, T.. Participation of both host and virus factors in induction of severe acute respiratory syndrome in F344 rats infected with SARS coronavirus, J. Virol., 2007, 81, 1848-1857.
  73. Naganawa, S.; Yokoyama, M.; Shiino, T.; Suzuki, T.; Ishigatsubo, Y.; Ueda, A.; Shirai, A.; Takeno, M.; Hayakawa, S.; Sato, S.; Tochikubo, O.; Kiyoura, S.; Sawada, K.; Ikegami, T.; Kanda, T.; Kitamura, K.; Sato, H.. Net Positive Charge of HIV-1 CRF01_AE V3 Sequence Regulates Viral Sensitivity to Humoral Immunity, PLoS ONE, 2008, 3, e3206.
  74. Nayeem, A.; Sitkoff, D.; Krystek, S., Jr.. A comparative study of available software for high-accuracy homology modeling: From sequence alignments to strucutural models, Protein Science., 2006, 15, 808-824.
  75. Nishigaya, Y.; Fujimoto, Z.; Yamazaki, T.. Optimized inhibition assays reveal different inhibitory responses of hydroxylamine oxidoreductases from beta- and gamma-proteobacterial ammonium-oxidizing bacteria, Biochem Biophys Res Commun., 2016, 476, 127-133.
  76. 西ヶ谷有輝、土屋渉、藤本瑞、鈴木倫太郎、山崎俊正「構造ベース創農薬による硝化抑制剤の開発~農薬開発に必要なイノベーション~」日本農薬学会誌, 2019, 44(1), 44-51.
  77. Nishioka, T.; Endo-Umeda, K.; Ito, Y.; Shimoda, A.; Takeuchi, A.; Tode, C.; Hirota, Y.; Osakabe, N.; Makishima, M.; Suhara, Y.. Synthesis and In Vitro Evaluation of Novel Liver X Receptor Agonists Based on Naphthoquinone Derivatives, Molecules, 2019, 24, 4316.
  78. Niwa, T.; Asaki, T.; Kimura, S.. NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor, Analytical Chemistry Insights., 2007, 2, 93-106.
  79. Ogola, H., J., O.; Kamiike, T.; Hashimoto, N.; Ashida H.; Ishikawa T.; Shibata H.; Sawa Y.. Molecular characterization of a novel peroxidase from the cyanobacterium Anabaena sp. strain PCC 7120. Applied and Environmental Microbiology, 2009, 75, 7509-7518.
  80. Oka, T.; Yamamoto, M.; Yokoyama, M.; Ogawa, S.; Hansman, G. S.; Katayama, K.; Miyashita, K.; Takagi, H.; Tohya, Y.; Sato, H.; Takeda, N.. Highly conserved configuration of catalytic amino acid residues among calicivirus-encoded proteases,J. Virol., 2007, 81, 6798-6806.
  81. Okamoto, M.; Takayama, K.; Shimizu, T.; Ishida, K.; Takahashi, O.; Furuya, T.. Identification of Death-Associated Protein Kinases Inhibitors Using Structure-Based Virtual Screening,J. Med. Chem., 2009, 52, 7323-7327.
  82. Okazaki, S.; Suzuki, A.; Komeda, H.; Yamaguchi, S.; Asano, Y.; Yamane, T.. Crystal Structure and Functional Characterization of a D-Stereospecific Amino Acid Amidase fromOchrobactrum anthropi SV3, a New Member of the Penicillin-recognizing Proteins, J. Mol. Biol., 2007, 368, 79-91.
  83. Okazaki, S.; Suzuki, A.; Mizushima, T.; Kawano, T.;Komeda, H.; Asano, Y.; Yamane, T.. The Novel Structure of a Pyridoxal 5′-Phosphate-Dependent Fold-Type I Racemase, α-Amino-ε-caprolactam Racemase from Achromobacter obae, Biochemistry, 2009, 48, 941-950.
  84. 大川原 正、岡本良成、大塚雅巳 「薬剤耐性克服と創薬-イマチニブの耐性克服をどうするか」癌治療と宿主2005, vol.17 No.2, p63(157)-71(165)
  85. Pan, L.; Wen, Z.; Baudry, J.; Berenbaum, M.R.; Schuler, M.A.. Identification of Variable Amino Acids in the SRS1 Region of CYP6B1 Modulating Furanocoumarin Metabolism, Arch. Biochem. Biophys., 2004, 422, 31-41.
  86. Rose, S. Statistical design and application to combinatorial chemistry, Drug Discovery Today, 2002, 7, 133-138.
  87. Rupasinghe, S.; Baudry, J.; Schuler, M.A.. Common active site architecture and binding strategy of four phenylpropanoid P450s from Arabidopsis thaliana as revealed by molecular modeling, Protein Eng., 2003, 16, 721-731.
  88. Song, H.; Nakayama, E. E.; Yokoyama, M.; Sato, H.; Levy, J. A.; Shioda, T.. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5as, J. Virol., 2007, 81, 7280-7285.
  89. Sato, F.; Hojo, S.; Sun, H. On the Transferability of Force Field Parameters-With an ab Initio Force Field Developed For Sulfonamides, J. Phys. Chem. A , 2003, 107, 248-257.
  90. Schefzick, S.; Bradley, M.. Comparison of commercially available genetic algorithms: gas as variable selection tool, J. Comput. Aided. Mol. Des., 2004, 18, 511-521.
  91. Shimada, T.; Murayama, N.; Tanaka, K.; Takenaka, S; Imai, Y.; Hopkins, N.E.; Foroozesh, M.K.; Alworth, W.L.; Yamazaki, H.; Guengerich, F.P.; Komori, M.. Interaction of Polycyclic Aromatic Hydrocarbons with Human Cytochrome P450 1B1 in Inhibiting Catalytic Activity, Chem. Res. Toxicol., 2008, 21, 2313-2323.
  92. Shirakawa, K.; Takaori-kondo, A.; Yokoyama, M.; Izumi, T; Matsui, M.; Io, K.; Sato, T.; Sato, H.; Uchiyama, T.. Protein kinase A-mediated phosphorylation regulates the interaction between APOBEC3G and HIV-1 Vif, Nat. Struct. Mol. Biol., 2008, 15, 1184-1191.
  93. Soderling, S.H.; Beavo, J.A.. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions, Current Opinion in Cell Biology, 2000, 12, 174-179.
  94. Song, M.; Breneman, C.M.; Bi, J.; Sukumar, N.; Bennett, K.P.; Cramer, S.; Tugcu, N.. Prediction of protein retention times in anion-exchange chromotography systems using support vector regression, J. Chem. Inf. Comput. Sci., 2002, 42, 1347-1357.
  95. Takaoka, Y.; Ohta, M.; Takeuchi, A.; Miura, K.; Matsuo, M.; Sakaeda, T.; Sugano, A.; Nishio, H.. Ligand orientation governs conjugation capacity of UDP-glucuronosyltransferase 1A1, J. Biochem., 2010, 148, 25-28.
  96. Sutoh, S.; Uemura, Y.; Yamaguchi, Y.; Kiyotou, A.; Sugihara, R.; Nagayasu, M.; Kurokawa, M.; Ito, K.; Tsunekawa, N.; Nemoto, M.; Inagaki, K.; Tamura, T.. Redox-tuning of oxidizing disulfide oxidoreductase generates a potent disulfide isomerase, BBA Proteins and Proteomics, 2019, 1867, 194-201.
  97. Tamura, T.; Tsunekawa, N.; Nemoto, M.; Inagaki, K.; Hirano, T.; Sato, F.. Molecular evolution of gas cavity in [NiFeSe] hydrogenases resurrected in silico, Scientific Reports, 2016, 6.
  98. Tanaka, S.; Nishiyori, T.; Kojo, H.; Otsubo, R.; Tsuruta, M.; Kurogi, K.; Liu, MC.; Suiko, M.; Sakakibara, Y.; Kakuta, Y.. Structural basis for the broad substrate specificity of the human tyrosylprotein sulfotransferase-1, Scientific Reports, 2017, 7.
  99. Tanaka, T.; Okuda, T.; Yamamoto, Y.. Characterization of the CYP3A4 Active Site by Homology Modeling, Chem. Pharm. Bull., 2004, 52, 830-835.
  100. Tanaka, T.; Kamiguchi, N.; Okuda, T.; Yamamoto, Y.. Characterization of the CYP2C8 Active Site by Homology Modeling, Chem. Pharm. Bull., 2004, 52, 836-841.
  101. Teramoto, T.; Sakakibara, Y.; Inada, K.; Kurogi, K.;Liu, M.; Suiko, M.; Kimura, M.;Kakuta, Y.. Crystal structure of mSULT1D1, a mouse catecholamine sulfotransferase, FEBS Letters, 2008, 582, 3909-3914.
  102. Tomitori, H.; Suganami, A.; Saiki, R.; Mizuno, S.; Yoshizawa, Y.; Masuko, T.; Tamura, Y.; Nishimura, K.; Toida, T.; Williams, K.; Kashiwagi, K.; Igarashi, K. Structural Changes of Regulatory Domain Heterodimer of N-Methyl-d-aspartate Receptor Subunits GluN1 and GluN2B through the Binding of Spermine and Ifenprodil, J. Pharmacol. Exp. Ther., 2012,343. 82-90.
  103. Torimoto-katori, N.; Huang, R.; Kato, H.; Ohashi, R.; Xia, M. In Silico Prediction of hPXR Activators Using Structure-Based Pharmacophore Modeling, J. Pharm. Sci., 2017, in press.
  104. Ueno, Y.; Kato, T.; Sato, K.; Ito, Y.; Yoshida, M.; Inoue, T.; Shibata, A.; Ebihara, M.; Kitade, Y.. Synthesis and Properties of Nucleic Acid Analogues Consisting of a Benzene-Phosphate BackboneJ. Org. Chem., 2005, 70, 7925-7935.
  105. Warr, W.. Virtual high-throughput screening: Computational tools for drug discovery and design. Spectrum, Drug Discovery and Design, 2001, Issue 10, 1-16.
  106. Whitling, J.M.; Spreitzer, G.; Wright, D.M.. A combinatorial and informatics approach to CdS nanoclusters, Advanced Materials, 2000, 12, 1377-1380.
  107. Wildman, S.A.; Crippen, G.M. Prediction of physicochemical parameters by atomic coordinates, J. Chem. Inf. Comput. Sci., 1999, 39, 868-873.
  108. Xue, L.; Stahura, F.L.; Godden, J.W.; Bajorath, J.. Fingerprint scaling increases the probability of identifying molecules with similar activity in virtual screening calculations, J. Chem. Inf. Comput. Sci., 2001, 41, 746-53.
  109. Xue, L.; Godden, J.W.; Gao, H.; Bajorath, J.. Mini-fingerprints detect similar activity of receptor ligands previously recognized only by three-dimensional pharmacophore-based methods, J. Chem. Inf. Comput. Sci., 2001, 41, 394-401.
  110. Xue, L.; Bajorath, J.. Molecular descriptors for effective classification of biologically active compounds based on principal component analysis identified by a genetic algorithm, J. Chem. Inf. Comput. Sci., 2000, 40, 801-809.
  111. Xue, L.; Godden, J.W.; Bajorath, J.. Database searching for compounds with similar biological activity using short binary bit string representations, J. Chem. Inf. Comput. Sci., 1999, 39, 881-886.
  112. Xue, L.; Godden, J.W.; Gao, H.; Bajorath, J.. Identification of a preferred set of descriptors for compound classification based on principcal component analysis, J. Chem. Inf. Comput. Sci., 1999, 39, 669-704.
  113. Yamamoto, Y.; Shuto, S.; Tamura, Y.; Kodama, T.; Hoshika, S.; Ichikawa, S.; Ueno, Y.; Ohtsuka, E.; Komatsu, Y.; Matsuda, A.. Oligodeoxynucleotides Having a Loop Consisting of 3′-Deoxy-4′-C-(2-hydroxyethyl)thymidines Form Stable Hairpins. Biochemistry, 2004, 43, 1218-1227.
  114. Yasri, A.; Hartsough, D.. Toward an optimal procedure for variable selection and QSAR model building. J. Chem. Inf. Comput. Sci., 2001, 41, 8690-8699.
  115. Yoshida, K.; Niwa, T.Quantitative Structure-Activity Relationship Studies on Inhibition of HERG Potassium Channels. J. Chem. Inf. Model., 2006, 46, 1371-1378.
  116. Yoshikawa, Y.; Kobayashi, K.; Oishi, S.; Fujii, N.; Furuya, T.. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: New insight into CXCR4–FC131 interactions, Bioorganic & medicinal chemistry letters, 2012,22.2146-2150.
  117. Yoshikawa, Y.; Oishi, S.; Kubo, T.; Tanahara, N.; Fujii, N.; Furuya, T.. An optimized method of G-protein coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands, Journal of medicinal chemistry,2013.
  118.  

このページのトップへ

References citing ASEDock

    • Anraku, K.; Inoue, T.; Sugimoto, K.; Kudo, K.; Okamoto, Y.; Morii, T.; Mori, Y.; Otsuka, M.. Design and synthesis of biotinylated inositol 1,3,4,5-tetrakisphosphate targeting Grp1 pleckstrin homology domain, Bioorg. Med. Chem.,2011,19. 6833 – 6841.
    • Azuma, M.; Kabe, Y.; Kuramori, C.; Kondo, M.; Yamaguchi, Y.; Handa, H.. Adenine Nucleotide Translocator Transports Haem Precursors into Mitochondria, PLoS ONE, 2008,3. e3070.
    • Cen, X.; Nitta, A.; Ibi, D.; Zhao, Y.; Niwa, M.; Taguchi, K.; Hamada, M.; Ito, Y.; Ito, Y.; Wang, L.; Nabeshima, T.. Identification of Piccolo as a regulator of behavioral plasticity and dopamine transporter internalization, Mol Psychiatry, 2008,13.451-463.
    • Chutiwitoonchai, N.; Hiyoshi, M.; Mwimanzi, P.; Ueno, T.; Adachi, A.; Ode, H.; Sato, H.; Fackler, O. T.; Okada, S.; Suzu, S.. The Identification of a Small Molecule Compound That Reduces HIV-1 Nef-Mediated Viral Infectivity Enhancement, PLoS ONE, 2011,6.e27696.
    • Daiyasu, H.; Hirokawa, T.; Kamiya, N.; Toh, H.. Computational analysis of ligand recognition mechanisms by prostaglandin E2 (subtype 2) and D2 receptors, Theoretical Chemistry Accounts: Theory, Computation, and Modeling (Theoretica Chimica Acta), 2011,130.1131-1143.
    • Dau, P.; Sakai, H.; Hirano, M.; Ishibashi, H.; Tanaka, Y.; Kameda, K.; Fujino, T.; Kim, E.; Iwata, H.. Quantitative Analysis of the Interaction of Constitutive Androstane Receptor with Chemicals and Steroid Receptor Coactivator 1 Using Surface Plasmon Resonance Biosensor Systems: A Case Study of the Baikal Seal (Pusa sibirica) and the Mouse, Toxicological Sciences,2012
    • Govindaraj, R. G.; Manavalan, B.; Lee, G.; Choi, S.. Molecular Modeling-Based Evaluation of hTLR10 and Identification of Potential Ligands in Toll-Like Receptor Signaling, PLoS ONE, 2010,5. e12713-.
    • Hakamata, W.; Ishikawa, R.; Ushijima, Y.; Tsukagoshi, T.; Tamura, S.; Hirano, T.; Nishio, T.. Virtual ligand screening of ホア-glucosidase: Identification of a novel potent noncarbohydrate mimetic inhibitor, Bioorg. Med. Chem. Lett., 2012,22.62 – 64.
    • Hasegawa, M.; Yasuda, Y.; Tanaka, M.; Nakata, K.; Umeda, E.; Wang, Y.; Watanabe, C.; Uetake, S.; Kunoh, T.; Shionyu, M.; Sasaki, R.; Shiina, I.; Mizukamia, T.. A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor, European Journal of Medicinal Chemistry,2013
    • Hiasa, M.; Isoda, Y.; Kishimoto, Y.; Saitoh, K.; Kimura, Y.; Kanai, M.; Shibasaki, M.; Hatakeyama, D.; Kirino, Y.; Kuzuhara, T.. Inhibition of monoamine oxidase A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir, British Journal of Pharmacology, 2013.
    • Hidari, K. I.; Ikeda, K.; Watanabe, I.; Abe, T.; Sando, A.; Itoh, Y.; Tokiwa, H.; Morita, K.; Suzuki, T.. 3-O-sulfated glucuronide derivative as a potential anti-dengue virus agent, Biochem. Biophys. Res. Commun.,2012
    • Hirakawa, H.; Akita, H.; Fujiwara, T.; Sugai, M.; Kuhara, S.. Structural insight into the binding mode between the targeting domain of ALE-1 (92AA) and pentaglycine of peptidoglycan,Protein Engineering, Design and Selection,2009,22.385-391.
    • Hou, D.-X.; Kumamoto, T.. Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling, Antioxid. Redox Signaling,2010,13.691-719.
    • Huang, J.; Hamasaki, T.; Ozoe, F.; Ozoe, Y.. Single amino acid of an octopamine receptor as a molecular switch for distinct G protein couplings, Biochem. Biophys. Res. Commun.,2008,371.610-614.
    • Iijima, S.; Lee, Y.-J.; Ode, H.; Arold, S.; Kimura, N.; Yokoyama, M.; Sato, H.; Tanaka, Y.; Strebel, K.; Akari, H.. A non-canonical mu-1A-binding motif in the N-terminus of HIV-1 Nef determines its activity to down-regulate MHC-I in T lymphocytes, J. Virol., 2012
    • Indarte, M.; Madura, J. D.; Surratt, C. K.. Dopamine transporter comparative molecular modeling and binding site prediction using the LeuTAa leucine transporter as a template, Proteins: Struct., Funct., Bioinf.,2008,70.1033-1046.
    • Isogai, H.; Hirayama, N.. A Possible Molecular Mechanism of Immunomodulatory Activity of Bilirubin,International Journal of Medicinal Chemistry,2013
    • Isogai, H.; Miyadera, H.; Ueta, M.; Sotozono, C.; Kinoshita, S.; Tokunaga, K.; Hirayama, N.. In Silico Risk Assessment of HLA-A* 02: 06-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Caused by Cold Medicine Ingredients, Journal of Toxicology,2013
    • Iwai, Y.; Murakami, K.; Gomi, Y.; Hashimoto, T.; Asakawa, Y.; Okuno, Y.; Ishikawa, T.; Hatakeyama, D.; Echigo, N.; Kuzuhara, T.. Anti-Influenza Activity of Marchantins, Macrocyclic Bisbibenzyls Contained in Liverworts,PLoS ONE,2011,6.e19825.
    • Iwaki, T.; Shiota, K.; Al-Taweel, K.; Kobayashi, D.; Kobayashi, A.; Suzuki, K.; Yui, T.; Wadano, A.. Inhibition of RuBisCO cloned from Thermosynechococcus vulcanus and expressed in Escherichia coli with compounds predicted by Molecular Operation Environment (MOE), J. Biosci. Bioeng.,2008,105.26 – 33.
    • Izuhara, Y.; Yamaoka, N.; Kodama, H.; Dan, T.; Takizawa, S.; Hirayama, N.; Meguro, K.; van Ypersele de Strihou, C.; Miyata, T.. A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates, J Cereb Blood Flow Metab,2010,30.904-912.
    • Katayama, K.; Wakita, T.; Kanda, T.; Sato, H.. Structural basis for specific recognition of substrates by sapovirus protease, Genomics and computational science for virus research,2013,122.
    • Kimura, T.; Hamada, Y.; Stochaj, M.; Ikari, H.; Nagamine, A.; Abdel-Rahman, H.; Igawa, N.; Hidaka, K.; Nguyen, J.-T.; Saito, K.; Hayashi, Y.; Kiso, Y.. Design and synthesis of potent [beta]-secretase (BACE1) inhibitors with carboxylic acid bioisosteres,David W. Robertson Memorial Issue, Bioorg. Med. Chem. Lett.,2006,16.2380-2386.
    • Kumamoto, T.; Fujii, M.; Hou, D.-X.. Akt is a direct target for myricetin to inhibit cell transformation,Mol. Cell. Biochem.,2009,332.33-41.
    • Kusakabe, K.; Tada, Y.; Iso, Y.; Sakagami, M.; Morioka, Y.; Chomei, N.; Shinonome, S.; Kawamoto, K.; Takenaka, H.; Yasui, K.; Hamana, H.; Hanasaki, K.. Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists Bioorganic & Medicinal Chemistry,
      2013
    • Manavalan, B.; Murugapiran, S.; Lee, G.; Choi, S.. Molecular modeling of the reductase domain to elucidate the reaction mechanism of reduction of peptidyl thioester into its corresponding alcohol in non-ribosomal peptide synthetases, BMC Structural Biology, 2010,10.1
    • Masada, S.; Terasaka, K.; Oguchi, Y.; Okazaki, S.; Mizushima, T.; Mizukami, H.. Functional and Structural Characterization of a Flavonoid Glucoside 1,6-Glucosyltransferase from Catharanthus roseus, Plant Cell Physiol., 2009,50. 1401-1415.
    • Mori, M.; Matsuki, K.; Maekawa, T.; Tanaka, M.; Sriwanthana, B.; Yokoyama, M.; Ariyoshi, K.. Development of a Novel In Silico Docking Simulation Model for the Fine HIV-1 Cytotoxic T Lymphocyte Epitope Mapping, PLoS ONE, 2012,7. e41703.
    • Murayama, N.; Imai, N.; Nakane, T.; Shimizu, M.; Yamazaki, H.. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes,Biochem. Pharmacol.,2007,73.2020 – 2026.
    • Nishigori, M.; Nose, T.; Shimohigashi, Y.. Highly potent binding and inverse agonist activity of bisphenol A derivatives for retinoid-related orphan nuclear receptor RORγ,Toxicol. Lett.,2012,212.
      205 – 211.
    • Ogola, H. J. O.; Kamiike, T.; Hashimoto, N.; Ashida, H.; Ishikawa, T.; Shibata, H.; Sawa, Y.. Molecular Characterization of a Novel Peroxidase from the Cyanobacterium Anabaena sp. Strain PCC 7120, Appl. Environ. Microbiol.,2009,75.7509-7518.
    • Okai, M.; Kubota, K.; Fukuda, M.; Nagata, Y.; Nagata, K.; Tanokura, M/. Crystal Structure of [gamma]-Hexachlorocyclohexane Dehydrochlorinase LinA from Sphingobium japonicum UT26,J. Mol. Biol., 2010,403.260 – 269.
    • Okamoto, S.; Yu, F.; Harada, H.; Okajima, T.; Hattan, J.-i.; Misawa, N.; Utsumi, R.. A short-chain dehydrogenase involved in terpene metabolism from Zingiber zerumbet, FEBS Journal, 2011,278.2892-2900.
    • Ordonez, P.; Hamasaki, T.; Isono, Y.; Sakakibara, N.; Ikejiri, M.; Maruyama, T.; Baba, M.. Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives, Antimicrob. Agents Chemother.,2012
    • Qin, H.-M.; Miyakawa, T.; Jia, M. Z.; Nakamura, A.; Ohtsuka, J.; Xue, Y.-L.; Kawashima, T.; Kasahara, T.; Hibi, M.; Ogawa, J.; Tanokura M.. Crystal Structure of a Novel N-Substituted L-Amino Acid Dioxygenase from Burkholderia ambifaria AMMD,PloS one,2013,8.e63996.
    • Rahman, M. M.; Akiyoshi, Y.; Furutani, S.; Matsuda, K.; Furuta, K.; Ikeda, I.; Ozoe, Y.. Competitive antagonism of insect GABA receptors by iminopyridazine derivatives of GABA, Bioorganic & Medicinal Chemistry, 2012
    • Sakashita, H.; Akahoshi, F.; Yoshida, T.; Kitajima, H.; Hayashi, Y.; Ishii, S.; Takashina, Y.; Tsutsumiuchi, R.; Ono, S.. Lead optimization of [(S)-[gamma]-(arylamino)prolyl]thiazolidine focused on [gamma]-substituent: Indoline compounds as potent DPP-IV inhibitors, Bioorg. Med. Chem., 2007,15. 641-655.
    • Sassa, A.; Niimi, N.; Fujimoto, H.; Katafuchi, A.; Grテコz, P.; Yasui, M.; Gupta, R. C.; Johnson, F.; Ohta, T.; Nohmi, T.. Phenylalanine 171 is a molecular brake for translesion synthesis across benzo[a]pyrene-guanine adducts by human DNA polymerase kappa, Mutation Research/Genetic Toxicology and Environmental Mutagenesis,2011,718.10 – 17.
    • Seto, T.; Ozaki, M.; Nosaka, S.. Molecular Docking of Barbital Enantiomers to the Nicotinic Acetylcholine Receptor:Implications for the Mechanism of Anesthesia, CBIJ.,2012,12.14-24.
    • Suhara, Y.; Watanabe, M.; Motoyoshi, S.; Nakagawa, K.; Wada, A.; Takeda, K.; Takahashi, K.; Tokiwa, H.; Okano, T.. Synthesis of New Vitamin K Analogues as Steroid and Xenobiotic Receptor (SXR) Agonists: Insights into the Biological Role of the Side Chain Part of Vitamin K, J. Med. Chem., 2011,54. 4918-4922.
    • Suhara, Y.; Watanabe, M.; Nakagawa, K.; Wada, A.; Ito, Y.; Takeda, K.; Takahashi, K.; Okano, T.. Synthesis of Novel Vitamin K2 Analogues with Modification at the [omega]-Terminal Position and Their Biological Evaluation as Potent Steroid and Xenobiotic Receptor (SXR) Agonists, J. Med. Chem.,2011,54.4269-4273.
    • Tatara, Y.; Lin, Y.-C.; Bamba, Y.; Mori, T.; Uchida, T.. Dipentamethylene thiuram monosulfide is a novel inhibitor of Pin1, Biochem. Biophys. Res. Commun., 2009,384. 394-398.
    • Watanabe, Y.; Ibrahim, M. S.; Ellakany, H. F.; Kawashita, N.; Mizuike, R.; Hiramatsu, H.; Sriwilaijaroen, N.; Takagi, T.; Suzuki, Y.; Ikuta, K.. Acquisition of Human-Type Receptor Binding Specificity by New H5N1 Influenza Virus Sublineages during Their Emergence in Birds in Egypt, PLoS Pathog, 2011,7.e1002068.
    • Xue, Y.-L.; Miyakawa, T.; Hayashi, Y.; Okamoto, K.; Hu, F.; Mitani, N.; Furihata, K.; Sawano, Y.; Tanokura, M.. Isolation and Tyrosinase Inhibitory Effects of Polyphenols from the Leaves of Persimmon, Diospyros kaki, J. Agric. Food Chem., 2011,59.6011-6017.
    • Yamaguchi, H.; Akitaya, T.; Yu, T.; Kidachi, Y.; Kamiie, K.; Noshita, T.; Umetsu, H.; Ryoyama, K.. Molecular docking and structural analysis of cofactor-protein interaction between NAD<sup>+</sup> and 11β-hydroxysteroid dehydrogenase type 2, J. Mol. Model.,2011,.1-12.
    • Yamaguchi, H.; Akitayam,T.; Kidachi, Y.; Kamiie, K.; Umetsu, H.. Homology modeling and structural analysis of human γ-glutamylcysteine ligase catalytic subunit for antitumor drug development,J. Biophysical Chemistry,2012,3.238-248.
    • Yamaguchi, H.; Kidachi, Y.; Kamiie, K.; Noshita, T.; Umetsu, H.. Homology modeling and structural analysis of human P-glycoprotein,Bioinformation,2012,8 (22).1066-1074.
    • Yamaguchi, H.; Kidachi, Y.; Kamiie, K.; Noshita, T.; Umetsu, H.. Structural insight into the ligand-receptor interaction between glycyrrhetinic acid (GA) and the high-mobility group protein B1 (HMGB1)-DNA complex, Bioinformation,2012,8 (23).1147-1153.
    • Yamaguchi, H.; Yu, T.; Kidachi, Y.; Akitaya, T.; Yoshida, K.; Kamiie, K.; Noshita, T.; Umetsu, H.; Ryoyama, K.. Selective toxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells is potentially attributed to downregulation of glutathione, Biochimie,2011,93.1172 – 1178.
    • Yamaguchi, H.; Yu, T.; Noshita, T.; Kidachi, Y.; Kamiie, K.; Yoshida, K.; Akitaya, T.; Umetsu, H.; Ryoyama, K.. Ligand-receptor Interaction between Triterpenoids and the 11beta-Hydroxysteroid dehydrogenase type 2 (11beta HSD2) Enzyme Predicts Their Toxic Effects against Tumorigenic r/m HM-SFME-1 Cells, J. Biol. Chem., 2011,286. 36888-36897.
    • Yamakawa, N.; Suemasu, S.; Matoyama, M.; ichiro Tanaka, K.; Katsu, T.; Miyata, K.; Okamoto, Y.; Otsuka, M.; Mizushima, T.. Synthesis and biological evaluation of loxoprofen derivatives, Bioorganic & Medicinal Chemistry, 2011,19. 3299 – 3311.
    • Yokoyama, M.; Mori, H.; Sato, H.. Allosteric Regulation of HIV-1 Reverse Transcriptase by ATP for Nucleotide Selection, PLoS ONE,2010,5.e8867.
    • Yoshikane, Y.; Tamura, A.; Yokochi, N.; Ellouze, K.; Yamamura, E.; Mizunaga, H.; Fujimoto, N.; Sakamoto, K.; Sawa, Y.; Yagi, T.. Engineering Mesorhizobium loti pyridoxamine-pyruvate aminotransferase for production of pyridoxamine with l-glutamate as an amino donor, J. Mol. Catal. B: Enzym.,2010,67.104-110.

    このページのトップへ

    References citing AutoQSAR

      • Cherkasov, A.; Ban, F.; Santos-Filho, O.; Thorsteinson, N.; Fallahi, M.; Hammond, G. L.. An Updated Steroid Benchmark Set and Its Application in the Discovery of Novel Nanomolar Ligands of Sex Hormone-Binding Globulin, Journal of Medicinal Chemistry, 2008,51.
        2047-2056.
      • Hödl C, C.; Raunegger, K.; Strommer, R.; Ecker, G. F.; Kunert, O.; Sturm, S.; Seger, C.; Haslinger, E.; Steiner, R.; Strauss, W. S. L.; Schramm, H.-W. Syntheses and Antigestagenic Activity of Mifepristone Derivatives, Journal of Medicinal Chemistry, 2009,52. 1268-1274.
      • Hillebrecht, A.; Klebe, G.. Use of 3D QSAR Models for Database Screening: A Feasibility Study, Journal of Chemical Information and Modeling,2008,48.384-396.
      • Takahashi, J.; Hijikuro, I.; Kihara, T.; Murugesh, M. G.; Fuse, S.; Kunimoto, R.; Tsumura, Y.; Akaike, A.; Niidome, T.; Okuno, Y.; Takahashi, T.; Sugimoto, H.. Design, synthesis, evaluation and QSAR analysis of N1-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors, Bioorganic & Medicinal Chemistry Letters, 2010,20. 1718 – 1720.
      • Zhang, Y.; Hudock, M. P.; Krysiak, K.; Cao, R.; Bergan, K.; Yin, F.; Leon, A.; Oldfield, E.. Activity of Sulfonium Bisphosphonates on Tumor Cell Lines, Journal of Medicinal Chemistry, 2007,50. 6067-6079.
      • Zhu, H.; Tropsha, A.; Fourches, D.; Varnek, A.; Papa, E.; Gramatica, P.; Oberg, T.; Dao, P.; Cherkasov, A.; Tetko, I. V.. Combinatorial QSAR Modeling of Chemical Toxicants Tested against Tetrahymena pyriformis, Journal of Chemical Information and Modeling, 2008,48. 766-784.

    このページのトップへ

    関連製品

    BioSolveIT社製創薬支援ツール
    Daylight
    情報化学システム構築ツール
    PSILO
    タンパク質立体構造情報データベースシステム
    Chemotargets CLARITY
    ターゲット・作用機序予測プラットフォーム